Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years

Frank W.G. Leebeek, MD PhD, Karina Meijer, MD PhD, Michiel Coppens, MD, Peter Kampmann, MD, Robert Klamroth, Roger Schutgens, MD PhD MSc, Giancarlo Castaman, MD, Erhard Seifried, MD PhD, Joachim Schwaeble, Halvard Bönig, Eileen K Sawyer, PhD, Wolfgang A. Miesbach, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-139225

Published: 2020

Journal Articles

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Markus M. Mueller, MD, Hans van Remoortel, Patrick Meybohm, Kari Aranko, Mike Murphy, MD, Jeffrey L. Carson, MD, Erhard Seifried, MD PhD

Blood (2019) 134 (Supplement_1): 4982.

https://doi.org/10.1182/blood-2019-130601

Published: 2019

Journal Articles

Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B

Wolfgang Miesbach, MD PhD, Karina Meijer, Michiel Coppens, MD, Peter Kampmann, MD, Dr. Klamroth, Roger Schutgens, MD PhD MSc, Giancarlo Castaman, MD, Erhard Seifried, MD PhD, Joachim Schwaeble, Halvard Bönig, Eileen K Sawyer, PhD, Frank W.G. Leebeek, MD PhD

Blood (2019) 134 (Supplement_1): 2059.

https://doi.org/10.1182/blood-2019-122535

Published: 2019

Journal Articles

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Frank W.G. Leebeek, MD PhD, K Meijer, Michiel Coppens, MD PhD, Peter Kampmann, R Klamroth, Roger Schutgens, MD PhD, Giancarlo Castaman, Erhard Seifried, MD PhD, J Schwaeble, Halvard Bonig, MD MA, Eileen K Sawyer, Wolfgang A. Miesbach, MD PhD

Blood (2017) 130 (Supplement 1): 602.

https://doi.org/10.1182/blood.V130.Suppl_1.602.602

Published: 2017

Journal Articles

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Blood (2017) 130 (Supplement 1): 514.

https://doi.org/10.1182/blood.V130.Suppl_1.514.514

Published: 2017

Journal Articles

Inhibition of the Transcription Factor RUNX1 Causes Glycosyltransferase a Repression

Romy Kronstein-Wiedemann, Laura Schmidt, Jörn Lausen, Erhard Seifried, MD PhD, Torsten Tonn, MD PhD

Blood (2017) 130 (Supplement 1): 925.

https://doi.org/10.1182/blood.V130.Suppl_1.925.925

Published: 2017

Journal Articles

Downregulation of Glycosyltransferase a Expression By miRNA-331-3p Is Mediated By the Inhibition of the Transcription Factor SP1

Romy Kronstein-Wiedemann, Peter Bugert, Erhard Seifried, MD PhD, Torsten Tonn, MD PhD

Blood (2016) 128 (22): 1247.

https://doi.org/10.1182/blood.V128.22.1247.1247

Published: 2016

Journal Articles

High Efficiency Gene Correction in Hematopoietic Cells By Template-Free Crispr/Cas9 Genome Editing

Frank Schnütgen, PhD, Duran Sürün, Joachim Schwäble, PhD, Ana Tomasovic, PhD, Ralf Kühn, PhD, Stefan Stein, PhD, Nina Kurrle, PhD, Hubert Serve, MD, Erhard Seifried, MD PhD, Harald von Melchner, MD PhD

Blood (2016) 128 (22): 3507.

https://doi.org/10.1182/blood.V128.22.3507.3507

Published: 2016

Journal Articles

Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B

Frank W.G. Leebeek, MD PhD, Marco Tangelder, MD PhD, Karina Meijer, MD PhD, Giancarlo Castaman, Federica Cattaneo, MD, Michiel Coppens, MD PhD, Peter Kampmann, MD, Robert Klamroth, Roger E.G. Schutgens, MD PhD, Erhard Seifried, MD PhD, Joachim Schwaeble, MD, Halvard Boenig, MD PhD, Maaike Hendriks, Deya Corzo, MD FAAP, Wolfgang A. Miesbach, MD PhD

Blood (2016) 128 (22): 2314.

https://doi.org/10.1182/blood.V128.22.2314.2314

Published: 2016

Journal Articles

Mirna Regulation of Blood Group AB0 Genes

Romy Kronstein-Wiedemann, Dr., Paulina Nowakowska, Peter Milanov, Dr., Erhard Seifried, MD PhD, Torsten Tonn, MD PhD

Blood (2015) 126 (23): 158.

https://doi.org/10.1182/blood.V126.23.158.158

Published: 2015

Journal Articles

Mesenchymal Stromal Cells Suppress T-and B-Cells via Galectin-9 in a Donor Dependent Manner

Christopher Ungerer, Patricia Quade-Lyssy, Reinhard Henschler, Erhard Seifried, MD, PhD, Heinfried Radeke, Joerg Schuettrumpf, MD

Blood (2012) 120 (21): 1248.

https://doi.org/10.1182/blood.V120.21.1248.1248

Published: 2012

Journal Articles

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Patricia Quade-Lyssy, Christopher Ungerer, Peter Milanov, PhD, Erhard Seifried, MD, PhD, Jörg Schüttrumpf, MD

Blood (2012) 120 (21): 2048.

https://doi.org/10.1182/blood.V120.21.2048.2048

Published: 2012

Journal Articles

Lymphocyte-Activating Chemokines Are Potent Inducers of Sudden Arrest and Firm Adhesion in Mesenchymal Stromal Cells (MSCs) Under Shear Flow

Felicia Ciuculescu, Melanie Giesen, Erika Deak, Erhard Seifried, MD, PhD, Tanja Nicole Hartmann, Reinhard Henschler

Blood (2008) 112 (11): 2425.

https://doi.org/10.1182/blood.V112.11.2425.2425

Published: 2008

Journal Articles

The Small GTPase Rap1A Is Central for Migration and Adhesion of Mesenchymal Stromal Cells (MSCs)

Erika Deak, Brigitte Ruester, Stephan Göttig, Elena Puccetti, Ph.D., Martin Ruthardt, MD, Erhard Seifried, MD, PhD, Jürgen Scheele, MD, Reinhard Henschler

Blood (2008) 112 (11): 2426.

https://doi.org/10.1182/blood.V112.11.2426.2426

Published: 2008

Journal Articles

Establishment of an International Registry of Patients with Inherited FXIII Deficiency.

Vytautas Ivaskevicius, MD, Rainer Seitz, MD, PhD, Hans P. Kohler, MD, PhD, Laszlo Muszbek, PhD, Robert A.S. Ariens, PhD, Erhard Seifried, MD, PhD, Akitada Ichinose, PhD, Diane J. Nugent, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2007) 110 (11): 2149.

https://doi.org/10.1182/blood.V110.11.2149.2149

Published: 2007

Journal Articles

Five Novel Mutations in F13B Gene Resulting in FXIII Deficiency.

Vytautas Ivaskevicius, MD, Hannelore Rott, MD, Inge Scharrer, MD, PhD, Manuela Krause, MD, Erhard Seifried, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2007) 110 (11): 2150.

https://doi.org/10.1182/blood.V110.11.2150.2150

Published: 2007

Journal Articles

Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability.

Christof Geisen, MD, Matthias Watzka, PhD, Katja Sittinger, MD, Beate Luxembourg, MD, Michael Steffens, MD, Clemens R. Müller, PhD, Thomas F. Wienker, MD, PhD, Edelgard Lindhoff-Last, MD, PhD, Erhard Seifried, MD, PhD, Johannes Oldenburg, MD, PhD

Blood (2006) 108 (11): 719.

https://doi.org/10.1182/blood.V108.11.719.719

Published: 2006

Journal Articles

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Markus M. Mueller, MD, Hans-Ulrich Pfeiffer, Margaret Rheinschmidt, PhD, Bernd Poetzsch, MD, PhD, Johannes Oldenburg, MD, PhD, Laurence Corash, MD, PhD, Erhard Seifried, MD, PhD, Reinhard Henschler, MD, PhD

Blood (2006) 108 (11): 942.

https://doi.org/10.1182/blood.V108.11.942.942

Published: 2006

NARROW

AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Inhibition of the Transcription Factor RUNX1 Causes Glycosyltransferase a Repression

Downregulation of Glycosyltransferase a Expression By miRNA-331-3p Is Mediated By the Inhibition of the Transcription Factor SP1

High Efficiency Gene Correction in Hematopoietic Cells By Template-Free Crispr/Cas9 Genome Editing

Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B

Mirna Regulation of Blood Group AB0 Genes

Mesenchymal Stromal Cells Suppress T-and B-Cells via Galectin-9 in a Donor Dependent Manner

Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B

Lymphocyte-Activating Chemokines Are Potent Inducers of Sudden Arrest and Firm Adhesion in Mesenchymal Stromal Cells (MSCs) Under Shear Flow

The Small GTPase Rap1A Is Central for Migration and Adhesion of Mesenchymal Stromal Cells (MSCs)

Establishment of an International Registry of Patients with Inherited FXIII Deficiency.

Five Novel Mutations in F13B Gene Resulting in FXIII Deficiency.

Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability.

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only